Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to MyDekla 60
MyDekla 60 offers daclatasvir dihydrochloride in 60 mg tablets, formulated to treat chronic hepatitis C virus infection effectively.
Uses of MyDekla 60
MyDekla 60 is indicated for:
Treatment of chronic hepatitis C virus (HCV) infection
Combination therapy with other antiviral agents as prescribed by a healthcare provider
Benefits of MyDekla 60
Potent antiviral activity against HCV
High efficacy in achieving sustained virologic response (SVR)
Helps prevent progression of liver disease and reduces the risk of liver complications
Mechanism of Action of MyDekla 60
Daclatasvir in MyDekla 60 is a direct-acting antiviral agent that inhibits the NS5A protein of the hepatitis C virus, essential for viral replication and assembly. This action disrupts the viral lifecycle and leads to suppression of viral replication, ultimately clearing the infection